Janux Therapeutics (JANX) Equity Ratio (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Equity Ratio data on file, last reported at 0.92 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.92, down 4.97% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.92 (down 4.97% YoY), and the FY2025 annual result was 0.96, down 0.85% from the prior year.
• Equity Ratio slipped to 0.92 in Q1 2026 per JANX's latest filing, from 0.96 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.97 in Q1 2022 and troughed at 0.88 in Q2 2023.
• A 5-year average of 0.93 and a median of 0.94 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio fell 8.71% in 2023, then increased 8.47% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.88 in 2022, then gained by 2.73% to 0.91 in 2023, then advanced by 6.44% to 0.96 in 2024, then declined by 0.85% to 0.96 in 2025, then fell by 4.15% to 0.92 in 2026.
• Business Quant data shows JANX's Equity Ratio at 0.92 in Q1 2026, 0.96 in Q4 2025, and 0.95 in Q3 2025.